RegenCell BioScience Holdings (RGC)

[shinhari1309]

$RGC and IPO

The year 2021 has seen a huge number of 1,035 companies taking IPO in the US market; where the huge piece of the listings (35%) were in the biotech & healthcare sector.

Regencell Bioscience NASDAQ:[RGC] is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.

RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.

For year 2022, the company which shot to the moon since IPO is AMTD Digital NYSE:[HKD], a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.

Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.

Daily short volume (%) refers to the number of shares that have been shorted as compared to the total daily volume traded.

Comparison between the 2 companies can be found below article source;

[https://www.benzinga.com/amp/content/28316977]